Published in

Nature Research, npj Breast Cancer, 1(9), 2023

DOI: 10.1038/s41523-023-00534-1

Links

Tools

Export citation

Search in Google Scholar

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Journal article published in 2023 by Emma Zattarin, Daniele Presti, Luigi Mariani ORCID, Caterina Sposetti ORCID, Rita Leporati ORCID, Alice Menichetti, Chiara Corti ORCID, Chiara Benvenuti, Giovanni Fucà ORCID, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractWhether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.